News headlines about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Vital Therapies earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.3152860735107 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.01. During the same period last year, the business posted ($0.30) EPS.

Several brokerages recently commented on VTL. BidaskClub raised Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Zacks Investment Research cut Vital Therapies from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Vital Therapies presently has a consensus rating of “Hold” and a consensus price target of $8.00.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Vital Therapies (VTL) Share Price” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at

In other news, Director Muneer A. Satter acquired 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was acquired at an average cost of $3.53 per share, for a total transaction of $176,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Muneer A. Satter acquired 130,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were purchased at an average price of $4.01 per share, with a total value of $521,300.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 190,000 shares of company stock valued at $737,800. 32.60% of the stock is owned by corporate insiders.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Stock Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related stocks with our FREE daily email newsletter.